Distribution of Recombinant Adenovirus in the Cerebrospinal Fluid of Nonhuman Primates
- 20 September 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 10 (14) , 2347-2354
- https://doi.org/10.1089/10430349950016997
Abstract
Gene therapy by administration of vectors into the cerebrospinal fluid (CSF) may be used in treatment of leptomeningeal metastases (cancer gene therapy) as well as in treatment of neurodegenerative disorders, traumatic injury, and chronic pain. Recombinant adenoviruses are attractive vectors for intra-CSF administration because they can efficiently transfer genes into the nonreplicating cells of the central nervous system (CNS). In addition, they can be produced in high titers and, because no producers cells are introduced, the risk of CSF obstruction by clustering cells is circumvented. However, successful application requires favorable distribution dynamics, high transduction efficiency, and long-lasting transgene expression. In this study we examined the distribution of a recombinant adenovirus containing the lacZ gene after administration into the CSF of nonhuman primates. After intraventricular and suboccipital administration, homogeneous distribution of the vector along the meninges covering the brain and spinal cord was obtained, as demonstrated by extensive and intense blue staining of cells, predominantly in the arachnoid and pia mater. In one animal we also found beta-galactosidase activity in the cervical paraspinal fat and in one of the deep cervical lymph nodes, indicating drainage of the vector or vector products with CSF into cervical lymph. This route of vector clearance from the CNS may result in antigenic presentation and an effective immune response and may explain the sixfold higher serum antibody titers after intrathecal injection of adenovirus as compared with intranasal application in Fischer rats. We conclude that distribution dynamics of recombinant adenovirus after intra-CSF administration are excellent. However, because of the immune response elicited by the virus, even after administration to the CNS, development of immunomodulating strategies remains a challenge.Keywords
This publication has 26 references indexed in Scilit:
- Central Nervous System Delivery of Interleukin 4 by a Nonreplicative Herpes Simplex Type 1 Viral Vector Ameliorates Autoimmune DemyelinationHuman Gene Therapy, 1998
- Preclinical Testing of Recombinant Adenoviral Herpes Simplex Virus-Thymidine Kinase Gene Therapy for Central Nervous System MalignanciesNeurosurgery, 1997
- Treatment of leptomeningeal metastases in a rat model using a recombinant adenovirus containing the HSV-tk geneJournal of Neurosurgery, 1996
- Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral VectorsHuman Gene Therapy, 1996
- Nervous tissue as an immune compartment: the dialect of the immune response in the CNSImmunology Today, 1994
- Lung Gene Therapy: In Vivo Adenovirus-Mediated Gene Transfer to Rhesus Monkey Airway EpitheliumHuman Gene Therapy, 1994
- In Vivo Transfer and Expression of the lacZ Gene in the Mouse LungExperimental Lung Research, 1993
- Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new viewImmunology Today, 1992
- Ultrastructural morphology of the olfactory pathway for cerebrospinal fluid drainage in the rabbitJournal of Neurosurgery, 1986
- Some Observations on the Circulation of Phenosulfonpthalein in Cerebrospinal Fluid: Normal Flow and the Flow in HydrocephalusJournal of Neurosurgery, 1970